• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Eric Van Cutsem, Paulo Marcelo Gem Hoff, +15 authors Richard L. Schilsky
  • Medicine
  • British Journal of Cancer
  • 2004 (First Published: 1 March 2004)
  • This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phaseContinue Reading
  • H. Arkenau, Dirk Arnold, +9 authors Rainer Porschen
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2008 (First Published: 20 December 2008)
  • PURPOSE Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer.Continue Reading
  • Dominik Paul Modest, Ingrid Ricard, +14 authors Anke C Reinacher-Schick
  • Medicine
  • Annals of oncology : official journal of the…
  • 2016 (First Published: 1 September 2016)
  • BACKGROUND To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS ANDContinue Reading
  • C. I. Müller, Karsten Schulmann, +9 authors Ullrich Graeven
  • Medicine
  • International Journal of Colorectal Disease
  • 2008 (First Published: 1 November 2008)
  • Background and aimsMicrosatellite instability (MSI) is a potential indicator of prognosis in patients with colorectal cancer (CRC). To date, there are a limited number of studies which investigatedContinue Reading
  • Tanja Trarbach, Anke C Reinacher-Schick, +5 authors Ullrich Graeven
  • Medicine
  • Oncology Research and Treatment
  • 2010
  • Background: This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients withContinue Reading
  • Anke C Reinacher-Schick, Michael Geissler, +7 authors Wolff Schmiegel
  • Medicine
  • 2007 (First Published: 20 June 2007)
  • 4034 Background: Bevacizumab (Bev) combined with 5-FU/FA and both, irinotecan or oxaliplatin are standard regimens for mCRC. Recently, a phase III trial has demonstrated that infusional 5-FU can be...